Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Finding Human Experimental Infection Study With SARS-CoV-2 Omicron BA.5 Subvariant
NCT06478420Phase 1Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Aug 2024
- Primary completion
- Oct 2028
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of SARS-CoV-2 omicron virus in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of solicited and unsolicited adverse events, including severe adverse events at Day 180 and Selection of the optimal SARS-CoV-2 dose(s) at Day 14. Started Aug 2024; status: active, not recruiting.
02
Drugs
SARS-CoV-2 omicron virus
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06478420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478420.